Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Oncology

Osteosarcoma Lung Relapse: What Are the Treatments?

At a Glance

When osteosarcoma spreads to or returns in the lungs, surgery to remove all visible tumors may provide the best chance of long-term control for carefully selected patients. Chemotherapy, targeted medicines, radiation, ablation, and clinical trials may be considered when surgery is not possible.

If osteosarcoma spreads (metastasizes) or returns after initial treatment, the lungs are by far the most common place it goes. Hearing that the cancer has returned is emotionally difficult, and seeking a second opinion at a specialized sarcoma center is a very reasonable step to ensure all options are explored.

When routine chest CT scans detect new spots—often called nodules or pulmonary metastases—the multidisciplinary care team will review them carefully. Not every new spot is cancer; some can be scar tissue, inflammation, or an infection. The team will compare current scans to past ones, watch for growth over time, check for disease elsewhere, and sometimes recommend a biopsy to confirm whether the spots are a relapse. If osteosarcoma is confirmed in the lungs, the primary goal is often to safely treat or remove all visible signs of the disease.

Surgical Removal (Metastasectomy)

For osteosarcoma in the lungs, surgery to remove the tumors—called a pulmonary metastasectomy—often offers the best chance of long-term control for carefully selected patients [1][2]. Complete removal means no visible tumor remains on scans or during surgery, though it does not completely eliminate the risk of microscopic cancer remaining or guarantee the cancer will not return [1].

Surgery is generally considered the best option if:

  • The primary bone tumor (the original site of the cancer) is completely controlled [1].
  • There is no cancer elsewhere in the body that cannot be safely treated [1].
  • The surgical team believes they can completely remove all the spots in the lungs [1][2].
  • The patient will have enough healthy lung tissue left to breathe well (adequate pulmonary reserve) after the operation [2].

There is no strict rule on exactly how many spots can be safely removed. The decision is highly individualized and depends on the number, size, and exact location of the spots, how fast they are growing, the patient’s general health, and previous treatments [3][2].

Types of Surgery

Surgeons may use different approaches, balancing the need to find all tumors with the desire for a smoother recovery:

  • Open surgery (Thoracotomy): The surgeon makes a larger incision to directly see and feel the lung tissue. Because osteosarcoma nodules can be hard to spot on scans, a surgeon’s hands can often find tiny tumors that high-resolution CT scans missed [4][5]. However, open surgery usually involves more pain and a longer recovery.
  • Minimally invasive surgery (Thoracoscopy): Using small incisions and a camera, this approach generally has a faster recovery. It may be appropriate for selected patients, depending on the location of the spots, whether they are on one or both lungs, and the surgeon’s experience [5].

What to Expect With Surgery

Lung surgery typically involves a hospital stay of several days. Surgeons often perform a “wedge resection,” removing a small section of tissue around the tumor to spare as much healthy lung as possible. Patients usually wake up with a chest tube to drain fluid and air, and will be guided through breathing exercises to prevent pneumonia and expand the lungs. Recovery time varies, but patients can expect a period of reduced energy and some chest pain that the care team will help manage.

Repeat Surgeries

Because osteosarcoma can recur, spots may return in the lungs even after a successful surgery. If this happens, a second or third metastasectomy can sometimes be performed. Repeat operations can help carefully selected patients achieve long-term disease control, but the decision requires a fresh risk-benefit review because each surgery carries cumulative risks like scarring, air leaks, and loss of lung tissue [6][7].

Other Local Treatments

If surgery is not safe or possible, the care team might discuss other ways to treat individual tumors. Options like stereotactic body radiation therapy (highly targeted radiation) or thermal ablation (using heat or cold to destroy the tumor) are sometimes used. While the evidence for these is less established than for surgery, they can be options for symptom control or slowing disease progression when surgery isn’t feasible.

Systemic Therapies (Medications)

Medications that travel through the whole body (systemic therapies) are often used alongside surgery or when complete surgical removal isn’t possible.

  • Salvage Regimens: If tumors are growing rapidly or cannot be surgically removed, standard chemotherapy drugs may be used to try to shrink them or pause their growth [8][9]. Sometimes, this shrinkage can make an inoperable patient eligible for surgery, though this is not guaranteed [8].
  • Targeted Therapies: Multikinase inhibitors (such as regorafenib or apatinib) are pills that target specific pathways to slow or stop the growth of the cancer [10][11]. They are generally used when standard chemotherapy is no longer working. These drugs can cause significant side effects, including high blood pressure, hand-foot skin reactions, diarrhea, liver problems, bleeding or clotting issues, and impaired wound healing [10]. It is critical not to start or stop these drugs around the time of surgery without strict guidance from both your oncology and surgical teams.

The Role of Clinical Trials

When osteosarcoma returns, it is a good idea to ask your care team whether a clinical trial is appropriate for you [12]. Trials are voluntary and offer access to investigational treatments, though their benefits and risks are uncertain, and they may require extra visits or travel to a specialized center. Current research focuses on combining targeted drugs with chemotherapy [13][14] and new forms of immunotherapy (drugs that help the immune system recognize and attack cancer cells) [15]. While standard checkpoint inhibitors (a common type of immunotherapy) have rarely been effective on their own for relapsed osteosarcoma, clinical trials are testing new combinations [16].

When to Contact Your Care Team

If you or your child are experiencing a lung relapse or recovering from lung surgery, monitor for new symptoms.

  • Contact your oncology team promptly for a new or worsening cough, shortness of breath, persistent chest pain, coughing up small amounts of blood, or a fever.
  • Seek urgent or emergency care for severe or sudden breathing difficulty, severe chest pain, fainting, or coughing up significant amounts of blood.

Common questions in this guide

When osteosarcoma returns in the lungs, is surgery usually the best treatment?
For carefully selected patients, pulmonary metastasectomy, or surgery to remove lung tumors, may offer the best chance of long-term control. It is most feasible when the original bone tumor is controlled, all visible lung disease can be removed, there is no unsafe cancer elsewhere, and enough healthy lung will remain. Surgery cannot guarantee that the cancer will not return.
How do doctors tell whether a new lung spot is osteosarcoma?
A new lung nodule is not always cancer; it can also be scar tissue, inflammation, or infection. The team compares CT scans over time, looks for growth and cancer elsewhere, and may recommend a biopsy when the diagnosis remains uncertain.
Can osteosarcoma lung metastases be operated on again if they come back?
Sometimes a second or third pulmonary metastasectomy is possible for carefully selected patients and may provide additional disease control. Doctors weigh the number and location of tumors, overall health, previous operations, remaining lung function, and cumulative risks such as scarring, air leaks, and loss of lung tissue.
What treatments are available if lung surgery is not possible?
Options may include stereotactic body radiation therapy or thermal ablation for selected tumors, chemotherapy to shrink or slow the cancer, and targeted medicines such as regorafenib or apatinib. A clinical trial may also be appropriate, especially when standard treatments are no longer working.
What is recovery like after surgery for osteosarcoma in the lungs?
A lung operation often requires a hospital stay of several days, and many patients wake up with a chest tube. Breathing exercises, pain control, and gradual activity help recovery; temporary chest pain and low energy are common, but the timeline varies by the operation and the person's health.
Should someone with relapsed osteosarcoma ask about a clinical trial?
Yes, it is reasonable to ask whether a trial fits your situation, particularly when the disease has returned or standard treatments are limited. Trials may test combinations of targeted medicines, chemotherapy, or immunotherapy, but the benefits and risks are uncertain and extra travel or visits may be required.
Which symptoms after a lung relapse or surgery need urgent medical attention?
Contact the oncology team promptly for a new or worsening cough, shortness of breath, persistent chest pain, a small amount of blood when coughing, or a fever. Seek emergency care for severe or sudden breathing difficulty, severe chest pain, fainting, or coughing up a significant amount of blood.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the chance that all visible disease can be removed, and what is your recommended surgical approach for my anatomy?
  2. 2.How will the proposed surgery affect my lung capacity and what should I expect during recovery?
  3. 3.What happens if a spot cannot be removed during the procedure?
  4. 4.Will I need additional chemotherapy or targeted therapy before or after the surgery?
  5. 5.Are there any clinical trials at this center or nearby that I should consider, and how do their risks compare to standard treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    [Surgery for Pulmonary Metastases in Patients with Advanced Soft Tissue and Osteosarcomas].

    Macherey S, Hekmat K, Zarghooni K, et al.

    Zeitschrift fur Orthopadie und Unfallchirurgie 2017; (155(5)):567-574 doi:10.1055/s-0043-110010.

    PMID: 28637066
  2. 2

    Survival after pulmonary metastasectomy for relapsed osteosarcoma.

    Liu Z, Yin J, Zhou Q, et al.

    The Journal of thoracic and cardiovascular surgery 2022; (163(2)):469-479.e8 doi:10.1016/j.jtcvs.2020.10.137.

    PMID: 33349447
  3. 3

    Oligo-Recurrence of Osteosarcoma Patients: Treatment Strategies for Pulmonary Metastases.

    Iwata S, Yonemoto T, Iizasa T, et al.

    Annals of surgical oncology 2015; (22 Suppl 3()):S1332-8 doi:10.1245/s10434-015-4682-1.

    PMID: 26092699
  4. 4

    A 20-year retrospective analysis of CT-based pre-operative identification of pulmonary metastases in patients with osteosarcoma: A single-center review.

    Heaton TE, Hammond WJ, Farber BA, et al.

    Journal of pediatric surgery 2017; (52(1)):115-119 doi:10.1016/j.jpedsurg.2016.10.034.

    PMID: 27836366
  5. 5

    Thoracoscopy vs thoracotomy for the management of metastatic osteosarcoma: A Pediatric Surgical Oncology Research Collaborative Study.

    Lautz TB, Farooqui Z, Jenkins T, et al.

    International journal of cancer 2021; (148(5)):1164-1171 doi:10.1002/ijc.33264.

    PMID: 32818304
  6. 6

    Lung metastasectomy for osteosarcoma in children, adolescents, and young adults: proof of permanent cure.

    Pastorino U, Palmerini E, Porcu L, et al.

    Tumori 2023; (109(1)):79-85 doi:10.1177/03008916211053048.

    PMID: 34674575
  7. 7

    Outcomes and prognostic factors of repeat pulmonary metastasectomy.

    Kanzaki R, Watari H, Omura A, et al.

    Interdisciplinary cardiovascular and thoracic surgery 2024; (38(3)) doi:10.1093/icvts/ivae028.

    PMID: 38426364
  8. 8

    Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.

    Palmerini E, Jones RL, Marchesi E, et al.

    BMC cancer 2016; (16()):280 doi:10.1186/s12885-016-2312-3.

    PMID: 27098543
  9. 9

    Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation.

    Dhir A, Hayashi M, Bodlak A, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(23)):5314-5322 doi:10.1158/1078-0432.CCR-24-1339.

    PMID: 39360936
  10. 10

    Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

    Duffaud F, Mir O, Boudou-Rouquette P, et al.

    The Lancet. Oncology 2019; (20(1)):120-133 doi:10.1016/S1470-2045(18)30742-3.

    PMID: 30477937
  11. 11

    Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.

    Xie L, Xu J, Sun X, et al.

    The oncologist 2019; (24(7)):e542-e550 doi:10.1634/theoncologist.2018-0542.

    PMID: 30559126
  12. 12

    Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decade.

    Reich M, Dinart D, Bellio H, et al.

    International journal of cancer 2026; (158(3)):728-737 doi:10.1002/ijc.70157.

    PMID: 41017203
  13. 13

    Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.

    Xie L, Xu J, Sun X, et al.

    Nature communications 2025; (16(1)):10473 doi:10.1038/s41467-025-65467-8.

    PMID: 41290609
  14. 14

    Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.

    Gaspar N, Venkatramani R, Hecker-Nolting S, et al.

    The Lancet. Oncology 2021; (22(9)):1312-1321 doi:10.1016/S1470-2045(21)00387-9.

    PMID: 34416158
  15. 15

    Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group.

    Hingorani P, Krailo M, Buxton A, et al.

    European journal of cancer (Oxford, England : 1990) 2022; (172()):264-275 doi:10.1016/j.ejca.2022.05.035.

    PMID: 35809374
  16. 16

    Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.

    Boye K, Longhi A, Guren T, et al.

    Cancer immunology, immunotherapy : CII 2021; (70(9)):2617-2624 doi:10.1007/s00262-021-02876-w.

    PMID: 33580363

This page provides general information about treating osteosarcoma that has spread to or returned in the lungs and does not constitute medical advice. Your oncology and surgical teams can recommend the safest plan for your specific situation.

Get notified when new evidence is published on Osteosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.